Clinical trial
A Prospective, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma.
NCT05461235 is registered in ClinicalTrials.gov with China Medical University, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma.
- Lead sponsor
- China Medical University, China
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 15, 2022
- Completion date
- December 1, 2025
- Enrollment
- 1 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
dc-cell, gastrointestinal tumours, nk-cell, pd-1 antibody